Shares of Teleflex Incorporated (NYSE:TFX) have been assigned an average rating of “Buy” from the eight research firms that are covering the stock. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $208.60.
TFX has been the subject of a number of recent research reports. Deutsche Bank AG upped their price objective on Teleflex from $192.00 to $213.00 and gave the stock a “buy” rating in a research note on Wednesday, March 15th. Needham & Company LLC initiated coverage on Teleflex in a report on Monday, March 6th. They issued a “buy” rating and a $221.00 price objective for the company. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $217.00 target price for the company in a report on Tuesday, March 14th. Stephens raised Teleflex from an “equal weight” rating to an “overweight” rating in a report on Friday, February 24th. Finally, Jefferies Group LLC reissued a “hold” rating on shares of Teleflex in a research report on Monday, March 27th.
Teleflex (NYSE:TFX) traded up 1.31% during midday trading on Monday, hitting $196.04. 32,800 shares of the stock were exchanged. Teleflex has a one year low of $136.53 and a one year high of $211.22. The firm has a 50-day moving average price of $198.01 and a 200-day moving average price of $175.61. The stock has a market cap of $8.82 billion, a P/E ratio of 40.69 and a beta of 0.93.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 4th. The medical technology company reported $1.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.11. Teleflex had a return on equity of 15.66% and a net margin of 15.09%. The company had revenue of $487.90 million for the quarter, compared to analyst estimates of $472.81 million. During the same period in the prior year, the company posted $1.52 EPS. Teleflex’s quarterly revenue was up 14.8% on a year-over-year basis. On average, equities research analysts anticipate that Teleflex will post $8.16 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Monday, May 15th will be given a $0.34 dividend. The ex-dividend date of this dividend is Thursday, May 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.70%. Teleflex’s dividend payout ratio is currently 23.49%.
In related news, Director Stephen K. M.D. Klasko sold 5,200 shares of Teleflex stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $193.56, for a total value of $1,006,512.00. Following the sale, the director now owns 12,880 shares of the company’s stock, valued at $2,493,052.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John Deren sold 2,246 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $194.07, for a total value of $435,881.22. Following the transaction, the vice president now directly owns 3,989 shares in the company, valued at approximately $774,145.23. The disclosure for this sale can be found here. 2.15% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in TFX. Pennsylvania Trust Co increased its stake in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock worth $419,000 after buying an additional 15 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in Teleflex by 3.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,175 shares of the medical technology company’s stock worth $213,000 after buying an additional 35 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Teleflex by 0.6% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,553 shares of the medical technology company’s stock worth $1,270,000 after buying an additional 37 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Teleflex by 0.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,560 shares of the medical technology company’s stock worth $1,271,000 after buying an additional 38 shares during the period. Finally, Advisor Group Inc. boosted its position in Teleflex by 2.5% in the third quarter. Advisor Group Inc. now owns 1,900 shares of the medical technology company’s stock worth $320,000 after buying an additional 47 shares during the period. Institutional investors own 93.02% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.